drugset
drugset / Trial / NCT00612066

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

NCT00612066 ↗

Phase 2 Terminated 2 enrolled Jonsson Comprehensive Cancer Center National Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed ACTH-secreting pituitary tumor (Cushing disease).

Timeline

Start
2007-04
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule — Oral

Indications

ACTH-dependent Cushing syndrome